Emmaus Medical
Emmaus Life Sciences, Inc.: Clinical trial for sickle cell anemia.
Launch date
Employees
Market cap
CAD4.1m
Enterprise valuation
CAD45m (Public information from Sep 2024)
Share price
$0.0231 EMMA
Torrance California (HQ)
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 22.8m | 23.2m | 20.6m | 18.4m | 29.6m | 21.3m | 22.8m |
| % growth | - | 2 % | (11 %) | (11 %) | 61 % | (28 %) | 7 % |
| EBITDA | (8.2m) | <1m | (8.0m) | (6.6m) | 2.5m | - | - |
| % EBITDA margin | (36 %) | - | (39 %) | (36 %) | 9 % | - | - |
| Profit | (54.8m) | 1.1m | (15.9m) | (10.6m) | (3.7m) | - | - |
| % profit margin | (241 %) | 5 % | (77 %) | (58 %) | (13 %) | - | - |
| R&D budget | 2.2m | 2.4m | 4.1m | 1.7m | 1.2m | - | - |
| R&D % of revenue | 10 % | 10 % | 20 % | 9 % | 4 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $1.0m | Early VC | |
| N/A | $3.7m | Debt | |
| N/A | $7.5m | Debt | |
N/A | Debt | ||
| N/A | $20.0m | Early VC | |
| N/A | $20.0m | Early VC | |
$30.0m | Debt | ||
| N/A | $12.0m | Debt | |
| N/A | N/A | IPO | |
$25.0m | Post IPO Equity | ||
| Total Funding | CAD55.9m | ||
Related Content
Recent News about Emmaus Medical
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.